| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 8.6 | 9.8 |
| Gross profit | 4.8 | 5.6 |
| Profit before tax | 3.4 | 3.3 |
| Net income | 2.8 | 2.6 |
| EPS (diluted, $ a share) | $0.88 | $0.82 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +5.9% |
|---|---|
| Revenue, year on year | -12.1% |
| Gross margin | 56.1% |
| Operating margin | 32.4% |
10-Q filed with the SEC, NASDAQ: UTMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Utah Medical Products Inc: key numbers
- Share price
- $72.36Close, Nov 16
- Market cap
- $206M
- Shares outstanding
- 2.85MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Utah Medical Products Inc
All →Utah Medical Products Dividend
Utah Medical Products, Inc. (UTMD) announced that its Board of Directors has approved a 1.6% increase to its regular quarterly cash dividend. The new dividend of $0.315 per share is payable on January 5, 2027, to shareholders of record as of December 17, 2026.
Utah Medical Products Chairman, CEO Kevin L. Cornwell Buys $66.8K of Stock
Kevin L. Cornwell, Chairman, CEO, bought 1,000 shares of Utah Medical Products Inc at $66.75 a share, worth $66.8K in total on Oct 29, 2026. Shares held after the trade: 189,472 (+0.5%).
- Value
- $66.8K
- Shares
- 1,000
- Price
- $66.75
- Role
- Chairman, CEO
- Holding change
- +0.5%
- Trade date
- Oct 29, 2026
Utah Medical Products Financial Results
Utah Medical Products reported its 3Q 2026 financial results, showing a 12.1% decrease in consolidated revenues to $8.6 million compared to the prior year. Despite the revenue decline caused by the loss of two major customers, the company achieved a 6% increase in net income for the quarter, supported by the acquisition of Orion Medical Supplies Ltd in August 2026.
- Term
- 3Q 2026